Illumina acquires Fluent BioSciences to accelerate single-cell analysis and discovery to a broader customer base

Core Insights - The acquisition of Fluent BioSciences by Illumina enhances Illumina's capabilities in single-cell research, a key growth area, and supports its multiomics growth strategy [1][2] - Fluent's single-cell analysis technology simplifies the process by eliminating the need for complex and costly instrumentation, making it more accessible to a wider range of customers [1] - The integration of Fluent's PIPseq™ V technology into Illumina's product portfolio aims to provide comprehensive solutions for single-cell analysis, enabling faster and more economical research [2] Company Overview - Illumina is a global leader in DNA sequencing and array-based technologies, focusing on innovation to improve human health through genomic insights [4] - The company serves various markets, including life sciences, oncology, reproductive health, and agriculture, with a commitment to maintaining an open NGS platform and supporting existing single-cell partnerships [2][4] Technology and Product Development - Fluent's PIPseq V technology offers high scalability, capable of processing from 100 cells to 1 million, and excels in detecting cell types often missed by current methods [1] - The acquisition, which closed on July 9, 2024, was funded with cash on hand, indicating a strategic investment in enhancing Illumina's product offerings [2]